Crossmark Global Holdings Inc. Has $1.18 Million Holdings in Globe Life Inc. $GL

Posted by Stanley Muller on May 14th, 2026

Crossmark Global Holdings Inc. decreased its stake in shares of Globe Life Inc. (NYSE:GL – Free Report) by 58.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,424 shares of the company’s stock after selling 11,642 shares during the period. Crossmark Global Holdings Inc.’s holdings in Globe Life were worth $1,178,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in GL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Globe Life by 6.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,391 shares of the company’s stock valued at $1,237,000 after acquiring an additional 607 shares in the last quarter. NewEdge Advisors LLC boosted its stake in Globe Life by 368.1% in the 1st quarter. NewEdge Advisors LLC now owns 6,806 shares of the company’s stock worth $897,000 after purchasing an additional 5,352 shares during the period. Goldman Sachs Group Inc. increased its holdings in Globe Life by 11.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 563,021 shares of the company’s stock worth $74,161,000 after purchasing an additional 58,163 shares in the last quarter. Empowered Funds LLC acquired a new stake in shares of Globe Life in the 1st quarter valued at about $428,000. Finally, Focus Partners Wealth raised its stake in shares of Globe Life by 8.3% in the 1st quarter. Focus Partners Wealth now owns 8,559 shares of the company’s stock valued at $1,127,000 after purchasing an additional 656 shares during the period. 81.61% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Globe Life

In other news, CFO Thomas Peter Kalmbach sold 15,637 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $153.65, for a total value of $2,402,625.05. Following the completion of the sale, the chief financial officer owned 45,335 shares of the company’s stock, valued at approximately $6,965,722.75. This represents a 25.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO James Matthew Darden sold 18,318 shares of the firm’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $145.10, for a total transaction of $2,657,941.80. Following the completion of the transaction, the chief executive officer directly owned 51,093 shares of the company’s stock, valued at $7,413,594.30. This represents a 26.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 107,147 shares of company stock valued at $16,086,366. 2.11% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on GL shares. Truist Financial upped their price objective on Globe Life from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Friday, April 24th. Piper Sandler raised Globe Life to a “strong-buy” rating in a research report on Thursday, April 2nd. Texas Capital upgraded Globe Life to a “strong-buy” rating in a research note on Wednesday, March 18th. JPMorgan Chase & Co. upped their price target on Globe Life from $180.00 to $181.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Finally, Wells Fargo & Company raised their price target on shares of Globe Life from $171.00 to $172.00 and gave the stock an “overweight” rating in a research note on Friday, April 10th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $172.67.

View Our Latest Report on Globe Life

Globe Life Trading Down 1.3%

Shares of NYSE:GL opened at $152.87 on Thursday. The company’s 50-day moving average price is $145.57 and its two-hundred day moving average price is $140.89. Globe Life Inc. has a one year low of $116.73 and a one year high of $156.69. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.07 and a quick ratio of 0.07. The stock has a market capitalization of $11.87 billion, a PE ratio of 10.57 and a beta of 0.50.

Globe Life (NYSE:GL – Get Free Report) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $3.43 earnings per share for the quarter, missing the consensus estimate of $3.46 by ($0.03). The company had revenue of $1.56 billion during the quarter, compared to the consensus estimate of $1.56 billion. Globe Life had a net margin of 19.38% and a return on equity of 20.94%. Globe Life’s revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.07 EPS. Globe Life has set its FY 2026 guidance at 15.400-15.90 EPS. On average, equities analysts forecast that Globe Life Inc. will post 15.56 EPS for the current fiscal year.

Globe Life Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Monday, July 6th will be paid a $0.33 dividend. This represents a $1.32 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Monday, July 6th. Globe Life’s dividend payout ratio (DPR) is currently 9.13%.

Globe Life Profile

(Free Report)

Globe Life, traded on the NYSE under the symbol GL, is a U.S.-based insurance holding company that underwrites and distributes a range of life and supplemental health insurance products. Through its subsidiary brands—Globe Life, American Income Life, Liberty National Life, United American Insurance Company and Family Heritage Life—it offers term life, whole life, fixed annuities and supplemental health coverage designed to meet the needs of individuals and families across various socioeconomic segments.

The company’s product suite includes low-cost, easy-to-understand life insurance policies, accidental death and dismemberment coverage, hospital indemnity plans and specified disease insurance.